Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Goodwill & Intangibles (2016 - 2023)

Sangamo Therapeutics (SGMO) has disclosed Goodwill & Intangibles for 11 consecutive years, with $51.6 million as the latest value for Q1 2023.

  • For Q1 2023, Goodwill & Intangibles fell 43.73% year-over-year to $51.6 million; the TTM value through Mar 2023 reached $51.6 million, down 43.73%, while the annual FY2022 figure was $88.3 million, 5.54% down from the prior year.
  • Goodwill & Intangibles hit $51.6 million in Q1 2023 for Sangamo Therapeutics, down from $88.3 million in the prior quarter.
  • Across five years, Goodwill & Intangibles topped out at $100.9 million in Q4 2020 and bottomed at $51.6 million in Q1 2023.
  • Average Goodwill & Intangibles over 5 years is $90.1 million, with a median of $92.5 million recorded in 2019.
  • Year-over-year, Goodwill & Intangibles soared 5810.85% in 2019 and then crashed 43.73% in 2023.
  • Sangamo Therapeutics' Goodwill & Intangibles stood at $92.4 million in 2019, then grew by 9.19% to $100.9 million in 2020, then dropped by 7.4% to $93.5 million in 2021, then dropped by 5.54% to $88.3 million in 2022, then crashed by 41.6% to $51.6 million in 2023.
  • According to Business Quant data, Goodwill & Intangibles over the past three periods came in at $51.6 million, $88.3 million, and $81.0 million for Q1 2023, Q4 2022, and Q3 2022 respectively.